BioSpace News Archive

Moderna, Inc.(Nasdaq:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the marketing authorization (MA) to include a booster dose of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), at the dose level for children (6-11 years) of 12.5mcg/12.5mcg (0.25 mL) at least three months after the last prior dose of a COVID-19 vaccine.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC).

BiondVax Pharmaceuticals Ltd. announced the pricing of its underwritten public offering with gross proceeds to the Company expected to be approximately $8,000,000, before deducting underwriting discounts and other expenses payable by the Company.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the grant to 17 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 79,096 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

Schrödinger, Inc. reported that on December 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 26,350 shares of the company’s common stock to seven newly hired employees, including two newly hired employees based outside of the United States.

Taysha Gene Therapies, Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced executive leadership changes effective immediately.

Centogene N.V. has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5450 since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.

AbbVie announced that the U.S. Food and Drug Administration has approved VRAYLAR® as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.

Adagene Inc. today announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC; liver cancer).

Tarsus Pharmaceuticals, Inc. today announced that Tarsus will be added to the NASDAQ Biotechnology Index ® (NASDAQ: NBI), effective December 19, 2022.